TY - JOUR
T1 - Allergen immunotherapy for allergic rhinoconjunctivitis
T2 - Protocol for a systematic review
AU - Dhami, Sangeeta
AU - Nurmatov, Ulugbek
AU - Roberts, Graham
AU - Pfaar, Oliver
AU - Muraro, Antonella
AU - Ansotegui, Ignacio J.
AU - Calderon, Moises
AU - Cingi, Cemal
AU - Demoly, Pascal
AU - Durham, Stephen
AU - Van Wijk, Ronald Gerth
AU - Halken, Susanne
AU - Hamelmann, Eckard
AU - Hellings, Peter
AU - Jacobsen, Lars
AU - Knol, Edward
AU - Linnemann, Desiree Larenas
AU - Lin, Sandra
AU - Maggina, Vivian
AU - Oude-Elberink, Hanneke
AU - Pajno, Giovanni
AU - Panwankar, Ruby
AU - Pastorello, Elideanna
AU - Pitsios, Constantinos
AU - Rotiroti, Giuseppina
AU - Timmermans, Frans
AU - Tsilochristou, Olympia
AU - Varga, Eva Maria
AU - Wilkinson, Jamie
AU - Williams, Andrew
AU - Worm, Margitta
AU - Zhang, Luo
AU - Sheikh, Aziz
N1 - Funding Information:
S. Dhami: support to co‑ordinate the undertaking of the systematic review; U. Nurmatov: support to undertake the review; G. Roberts: materials for research programme (ALK‑Abello), research grant (ALK‑Abello), advisory board (ALK‑Abello), speaker (Allergy Therapeutics, ALK‑Abelo); O. Pfaar: research grants, advisor and/or speaker (ALK Abelló, Allergopharma, Stallergenes, HAL Allergy, Artu Biologicals, Allergy Therapeutics/Bencard, Hartington, Lofarma, Novartis/Leti, GlaxoSmithKline, Essex Pharma, Cytos, Curalogic, Roxall, Biomay, Thermo Fisher, Circassia, European Union (FP‑7 Health‑2013 Innovation 1), Biotech Tools s.a., and Meda Pharma GmbH. Travel grants (HAL Allergy and Allergopharma). Advisor (Bencard, HAL Allergy, Novartis/Leti, Meda, ALK Abelló, Allergopharma, Biotech Tools s.a., GfK Bridgehead, Navigant Consult‑ ing, Sanofi, Guidepoint Global Advisors, Thermo Fisher and Stallergenes). Scientific Board Member of Mobile Chamber Experts (MCX), a GA2LEN Partner; A Muraro: Acting in consulting capacity for ALK, Meda Pharma, Nestle, Nutricia, Novartis. Grants from: Nestlé: Co–investigator for research proto‑ col, Nutricia: Co‑investigator for research protocols; IJ. Ansotegui: none; M. Calderon: lectures honorarium (ALK, Stallergens, Merck and Allergopharma), consultancy honorarium (ALK, Stallergenes and Hal); C. Cingi: none; P. Demoly: advisory board (ALK‑Abello, Allergopharma, Cirassia, Chiesi, DBV, Staller‑ gens, Thermo Fisher Scientific); S. Durham: advisory board (Merck), research grant or materials for research programme (ALK‑Abelo, Merck, Regeneron, Biotools); R. Gerth van Wijk : research grant (ALK Abello, DBV); S. Halken: GAP study Steering (ALK‑Abello); E.Hamelmann: research grant (AllergoPharma); P. Hellings: research grants (ALK‑Abello, GCK) and committee membership (MEDA, Stallergens, GSK); L. Jacobsen: consulting (EAMG, ALK), travel sup‑ port (EAMG), stock (>5000 euro)(ALK); E. Knol: Grant (HAL Allergy, Numico Research), consulting (HAL Allergy); D. Larenas‑Linnemann: none; S. Lin: none; V.Maggina: none; H.Oude‑Elberlink: financial support for Dutch Mastocytosis Centre (ALK‑Abello); G. Pajno: research grant (Stallergens); R. Panwankar: none; E. Pastorello: none; C. Pitsios: none; G. Rotiroti: research grant (ALK‑Abello); F.Timmermans: funding for Netherlands Anafylaxis Network (ALK‑Abello, MEDA); O.Tsilochristou: none; EM. Varga: research grant (ALK‑Abello), advisory committee (ALK‑Abello); J. Wilkinson: none; A. Williams: none; M. Worm: advisory committee (ALK‑Abello, Allergopharma, Bencard, Novartis, Meda); L. Zhang: none; A. Sheikh: support to co‑ordinate the undertaking of the system‑ atic review and development of the guidelines.
Publisher Copyright:
© 2016 Dhami et al.
PY - 2016/3/22
Y1 - 2016/3/22
N2 - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised. Conclusion: The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.
AB - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised. Conclusion: The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.
KW - Allergen immunotherapy
KW - Allergic rhinoconjunctivitis
KW - Allergy
KW - Rhinitis
UR - http://www.scopus.com/inward/record.url?scp=85006307466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006307466&partnerID=8YFLogxK
U2 - 10.1186/s13601-016-0099-6
DO - 10.1186/s13601-016-0099-6
M3 - Article
C2 - 27006751
AN - SCOPUS:85006307466
SN - 2045-7022
VL - 6
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 1
M1 - 12
ER -